Spots Global Cancer Trial Database for Flavopiridol in Treating Patients With Recurrent Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Flavopiridol in Treating Patients With Recurrent Prostate Cancer
Official Title: A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer
Study ID: NCT00003256
Conditions
Interventions
Study Description
Brief Summary: Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Detailed Description: OBJECTIVES: I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate. II. Assess the toxic effects of flavopiridol in this patient population. OUTLINE: Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation. Patients are followed every 3 months until death.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Beckman Research Institute, City of Hope, Duarte, California, United States
University of California Davis Cancer Center, Sacramento, California, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Contact Details
Name: George Wilding, MD
Affiliation: University of Wisconsin, Madison
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
